1-11 of 11
Gregory H. Reaman
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

The FDA Oncology Center of Excellence Scientific Collaborative: Charting a Course for Applied Regulatory Science Research in Oncology

Julie A. Schneider, Yutao Gong, Kirsten B. Goldberg, Paul G. Kluetz, Marc R. Theoret, Laleh Amiri-Kordestani, Julia A. Beaver, Lola Fashoyin-Aje, Nicole J. Gormley, Adnan A. Jaigirdar, Steven J. Lemery, Pallavi S. Mishra-Kalyani, Gregory H. Reaman, Donna R. Rivera, Wendy S. Rubinstein, Harpreet Singh, Rajeshwari Sridhara, Richard Pazdur
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (19): 5161–5167.
https://doi.org/10.1158/1078-0432.CCR-20-4429
Published: 01 October 2021
View article titled, The FDA Oncology Center of Excellence Scientific Collaborative: Charting a Course for Applied Regulatory Science Research in Oncology
Open the PDF for The FDA Oncology Center of Excellence Scientific Collaborative: Charting a Course for Applied Regulatory Science Research in Oncology in another window
Includes: Supplementary data
Journal Articles

FDA Approval Summary: Selumetinib for Plexiform Neurofibroma

Denise Casey, Suzanne Demko, Arup Sinha, Pallavi S. Mishra-Kalyani, Yuan-li Shen, Sachia Khasar, M. Anwar Goheer, Whitney S. Helms, Lili Pan, Yuan Xu, Jianghong Fan, Ruby Leong, Jiang Liu, Yuching Yang, Katherine Windsor, Mei Ou, Olen Stephens, Byeongtaek Oh, Gregory H. Reaman, Abhilasha Nair, Stacy S. Shord, Vishal Bhatnagar, Selena R. Daniels, Sharon Sickafuse, Kirsten B. Goldberg, Marc R. Theoret, Richard Pazdur, Harpreet Singh
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (15): 4142–4146.
https://doi.org/10.1158/1078-0432.CCR-20-5032
Published: 01 August 2021
View article titled, FDA Approval Summary: Selumetinib for Plexiform Neurofibroma
Open the PDF for FDA Approval Summary: Selumetinib for Plexiform Neurofibroma in another window
Journal Articles

Novel Therapeutic Interventions Early in the Disease Trajectory: Drug Development Beyond the Refractory Setting

Navid Hafez, Hope S. Rugo, Margaret A. Tempero, Elizabeth Fox, Gregory H. Reaman, Herbert Kim Lyerly, Desiree Walker, Patricia M. LoRusso
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (18): 4743–4747.
https://doi.org/10.1158/1078-0432.CCR-19-4035
Published: 15 September 2020
View article titled, Novel Therapeutic Interventions Early in the Disease Trajectory: Drug Development Beyond the Refractory Setting
Open the PDF for Novel Therapeutic Interventions Early in the Disease Trajectory: Drug Development Beyond the Refractory Setting in another window
Journal Articles

Challenges with Novel Clinical Trial Designs: Master Protocols

Michael Cecchini, Eric H. Rubin, Gideon M. Blumenthal, Kassa Ayalew, Howard A. Burris, Michele Russell-Einhorn, Hildy Dillon, H. Kim Lyerly, Gregory H. Reaman, Scott Boerner, Patricia M. LoRusso
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (7): 2049–2057.
https://doi.org/10.1158/1078-0432.CCR-18-3544
Published: 01 April 2019
View article titled, Challenges with Novel Clinical Trial Designs: Master Protocols
Open the PDF for Challenges with Novel Clinical Trial Designs: Master Protocols in another window
Journal Articles

The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications

Kenneth C. Anderson, Daniel Auclair, Gary J. Kelloff, Caroline C. Sigman, Hervé Avet-Loiseau, Ann T. Farrell, Nicole J. Gormley, Shaji K. Kumar, Ola Landgren, Nikhil C. Munshi, Michele Cavo, Faith E. Davies, Alessandra Di Bacco, Jennifer S. Dickey, Steven I. Gutman, Howard R. Higley, Mohamad A. Hussein, J. Milburn Jessup, Ilan R. Kirsch, Richard F. Little, Robert D. Loberg, Jens G. Lohr, Lata Mukundan, James L. Omel, Trevor J. Pugh, Gregory H. Reaman, Michael D. Robbins, A. Kate Sasser, Nancy Valente, Elena Zamagni
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (15): 3980–3993.
https://doi.org/10.1158/1078-0432.CCR-16-2895
Published: 01 August 2017
View article titled, The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications
Open the PDF for The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications in another window
Includes: Supplementary data
Journal Articles

Enrolling Adolescents in Disease/Target-Appropriate Adult Oncology Clinical Trials of Investigational Agents

Meredith K. Chuk, Yeruk Mulugeta, Michelle Roth-Cline, Nitin Mehrotra, Gregory H. Reaman
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (1): 9–12.
https://doi.org/10.1158/1078-0432.CCR-16-1367
Published: 02 January 2017
View article titled, Enrolling Adolescents in Disease/Target-Appropriate Adult Oncology Clinical Trials of Investigational Agents
Open the PDF for Enrolling Adolescents in Disease/Target-Appropriate Adult Oncology Clinical Trials of Investigational Agents in another window
Journal Articles

A Phase I Trial and Pharmacokinetic Study of 9- cis -Retinoic Acid (ALRT1057) in Pediatric Patients with Refractory Cancer: A Joint Pediatric Oncology Branch, National Cancer Institute, and Children’s Cancer Group Study

Peter C. Adamson, Brigitte C. Widemann, Gregory H. Reaman, Nita L. Seibel, Robert F. Murphy, Andrea F. Gillespie, Frank M. Balis
Journal: Clinical Cancer Research
Clin Cancer Res (2001) 7 (10): 3034–3039.
Published: 01 October 2001
View article titled, A Phase I Trial and Pharmacokinetic Study of 9- <em>cis</em> -Retinoic Acid (ALRT1057) in Pediatric Patients with Refractory Cancer: <subtitle>A Joint Pediatric Oncology Branch, National Cancer Institute, and Children’s Cancer Group Study</subtitle>
Open the PDF for A Phase I Trial and Pharmacokinetic Study of 9- <em>cis</em> -Retinoic Acid (ALRT1057) in Pediatric Patients with Refractory Cancer: <subtitle>A Joint Pediatric Oncology Branch, National Cancer Institute, and Children’s Cancer Group Study</subtitle> in another window
Journal Articles

A Phase I Clinical, Pharmacological, and Biological Trial of Interleukin 6 Plus Granulocyte-Colony Stimulating Factor after Ifosfamide, Carboplatin, and Etoposide in Children with Recurrent/Refractory Solid Tumors: Enhanced Hematological Responses but a High Incidence of Grade III/IV Constitutional Toxicities

Francisco Bracho, Mark D. Krailo, Violet Shen, Sharon Bergeron, Virginia Davenport, Wen Liu-Mares, Bruce R. Blazar, Angela Panoskaltsis-Mortari, Carmella van de Ven, Rita Secola, Matthew M. Ames, Joel M. Reid, Gregory H. Reaman, Mitchell S. Cairo
Journal: Clinical Cancer Research
Clin Cancer Res (2001) 7 (1): 58–67.
Published: 01 January 2001
View article titled, A Phase I Clinical, Pharmacological, and Biological Trial of Interleukin 6 Plus Granulocyte-Colony Stimulating Factor after Ifosfamide, Carboplatin, and Etoposide in Children with Recurrent/Refractory Solid Tumors: Enhanced Hematological Responses but a High Incidence of Grade III/IV Constitutional Toxicities
Open the PDF for A Phase I Clinical, Pharmacological, and Biological Trial of Interleukin 6 Plus Granulocyte-Colony Stimulating Factor after Ifosfamide, Carboplatin, and Etoposide in Children with Recurrent/Refractory Solid Tumors: Enhanced Hematological Responses but a High Incidence of Grade III/IV Constitutional Toxicities in another window
Journal Articles

Residual Bone Marrow Leukemic Progenitor Cell Burden after Induction Chemotherapy in Pediatric Patients with Acute Lymphoblastic Leukemia

Fatih M. Uckun, Linda Stork, Nita Seibel, Mireille Sarquis, Charles Bedros, Harland Sather, Martha Sensel, Gregory H. Reaman, Paul S. Gaynon
Journal: Clinical Cancer Research
Clin Cancer Res (2000) 6 (8): 3123–3130.
Published: 01 August 2000
View article titled, Residual Bone Marrow Leukemic Progenitor Cell Burden after Induction Chemotherapy in Pediatric Patients with Acute Lymphoblastic Leukemia
Open the PDF for Residual Bone Marrow Leukemic Progenitor Cell Burden after Induction Chemotherapy in Pediatric Patients with Acute Lymphoblastic Leukemia in another window
Journal Articles

Expression of Dominant-Negative Ikaros Isoforms in T-Cell Acute Lymphoblastic Leukemia

Lei Sun, Mya-Lisa Crotty, Martha Sensel, Harland Sather, Christopher Navara, James Nachman, Peter G. Steinherz, Paul S. Gaynon, Nita Seibel, Chen Mao, Alexei Vassilev, Gregory H. Reaman, Fatih M. Uckun
Journal: Clinical Cancer Research
Clin Cancer Res (1999) 5 (8): 2112–2120.
Published: 01 August 1999
View article titled, Expression of Dominant-Negative Ikaros Isoforms in T-Cell Acute Lymphoblastic Leukemia
Open the PDF for Expression of Dominant-Negative Ikaros Isoforms in T-Cell Acute Lymphoblastic Leukemia in another window
Journal Articles

Phase I Trial of Docetaxel with Filgrastim Support in Pediatric Patients with Refractory Solid Tumors: A Collaborative Pediatric Oncology Branch, National Cancer Institute and Children‘s Cancer Group Trial

Nita L. Seibel, Susan M. Blaney, Michelle O‘Brien, Mark Krailo, Ray Hutchinson, Revonda B. Mosher, Frank M. Balis, Gregory H. Reaman
Journal: Clinical Cancer Research
Clin Cancer Res (1999) 5 (4): 733–737.
Published: 01 April 1999
View article titled, Phase I Trial of Docetaxel with Filgrastim Support in Pediatric Patients with Refractory Solid Tumors: A Collaborative Pediatric Oncology Branch, National Cancer Institute and Children‘s Cancer Group Trial
Open the PDF for Phase I Trial of Docetaxel with Filgrastim Support in Pediatric Patients with Refractory Solid Tumors: A Collaborative Pediatric Oncology Branch, National Cancer Institute and Children‘s Cancer Group Trial in another window